Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UNC10217938A HCl (UNC7938 HCl) 是具有寡核苷酸 (oligonucleotides) 增强作用的 3-deazapteridine 类似物, 通过调节寡核苷酸在细胞内的运输和从内体中的释放来增强寡核苷酸的作用。UNC10217938A HCl 还增强了 siRN 和反义寡核苷酸的作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,300 | 现货 | ||
5 mg | ¥ 5,570 | 现货 | ||
10 mg | ¥ 7,790 | 现货 | ||
25 mg | ¥ 11,500 | 现货 | ||
50 mg | ¥ 15,600 | 现货 | ||
100 mg | ¥ 20,800 | 现货 |
产品描述 | UNC10217938A HCl (UNC7938 HCl) is a 3-deazapteridine analog. UNC10217938A HCl exhibits strong oligonucleotide enhancing effects. UNC10217938A HCl can modulate their intracellular trafficking and release from endosomes, leading to enhance oligonucleotides effects. UNC10217938A HCl also enhances the effects of siRNA and antisense oligonucleotides. |
体外活性 | UNC10217938A HCl strongly enhances luciferase induction in HelaLuc705 cells when used in the 5-25 µM range and are substantially more effective and potent than Retro-1. As compared to splice switching oligonucleotide (SSO) alone, UNC10217938A HCl provids a 60-fold enhancement at 10 µM and 220-fold at 20 µM, in contrast to a 11-fold enhancement for 100 µM Retro-1[1]. UNC10217938A HCl can substantially enhance effects of receptor targeted oligonucleotide conjugates. UNC10217938A HCl also can enhance effects of uncharged morpholino oligonucleotides as well as negatively charged oligonucleotides[1]. Exposure of cells to UNC10217938A HCl leads to a major reduction in co-localization of the TAMRA-oliogonucleotide with the late endosome marker Rab7, but had little effect on co-localization with the lysosomal marker LAMP-1. UNC10217938A HCl causes partial release of oligonucleotide from late endosomes to the cytosol followed by nuclear accumulation[1]. |
体内活性 | Systemic treatment with SSO623 followed by administration of UNC10217938A HCl (7.5 mg/kg; intravenous injection) produces distinct increases in EGFP fluorescence in liver, kidney and heart in EGFP654 mice[1]. |
别名 | UNC10217938A HCl(1347749-97-6 Free base), UNC7938 HCl |
分子量 | 493.00 |
分子式 | C26H29ClN6O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (101.41 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0284 mL | 10.142 mL | 20.284 mL | 50.7099 mL |
5 mM | 0.4057 mL | 2.0284 mL | 4.0568 mL | 10.142 mL | |
10 mM | 0.2028 mL | 1.0142 mL | 2.0284 mL | 5.071 mL | |
20 mM | 0.1014 mL | 0.5071 mL | 1.0142 mL | 2.5355 mL | |
50 mM | 0.0406 mL | 0.2028 mL | 0.4057 mL | 1.0142 mL | |
100 mM | 0.0203 mL | 0.1014 mL | 0.2028 mL | 0.5071 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
UNC10217938A HCl Others UNC10217938A HCl(1347749-97-6 Free base) UNC7938 HCl UNC10217938A HCl(1347749-97-6 Free base) Inhibitor inhibitor inhibit